利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.02 秒)

    Propanolaminomethyltetralines, their preparation and pharmaceutical composition comprising same
    3.
    发明申请
    Propanolaminomethyltetralines, their preparation and pharmaceutical composition comprising same 失效
    丙醇氨基甲基四氢萘酯，其制备方法和包含它们的药物组合物

    公开(公告)号：US20050054641A1

    公开(公告)日：2005-03-10

    申请号：US10497379

    申请日：2002-12-02

    申请人： Laura Barzaghi ,  Roberto Cecchi ,  Nunzia Viviani

    发明人： Laura Barzaghi ,  Roberto Cecchi ,  Nunzia Viviani

    IPC分类号： C07D319/22 ,  A61K31/138 ,  A61K31/18 ,  A61K31/357 ,  A61P1/00 ,  A61P1/04 ,  A61P1/14 ,  A61P3/04 ,  A61P3/10 ,  A61P15/00 ,  A61P15/06 ,  A61P25/18 ,  A61P25/24 ,  A61P27/06 ,  C07B53/00 ,  C07C217/74 ,  C07C311/08 ,  C07D265/36 ,  A61K31/428 ,  A61K31/538 ,  C07C229/34 ,  C07D263/52

    CPC分类号： C07C311/08 ,  C07C2602/10

    摘要： The invention concerns compounds of formula (1), wherein A is a group of formula (a) or (b), wherein: R represents a hydrogen or halogen atom, a —S(O)z(C1-C4)Alk wherein z is 0, 1 or 2, a —NHSO2(C1-C4)Alk, —SO2NH(C1-C4)Alk, —NHSO2—(C1-C4)Alk-phenyl or —NHSO2-phenyl group, said phenyl capable of bearing a halogen atom, a (C1-C4)Alk group or a (C1-C6)alkoxy group; R1 represents a hydrogen atom or a —(C1-C4)Alk, —CO(C1-C4)Alk, —(C1-C4)Alk-phenyl or —CO-phenyl group, said phenyl capable of bearing a halogen atom or a —(C1-C4)Alk or (C1-C6)alkoxy group; R2 is a hydrogen atom, a —SO2(C1-C4)Alk, —SO2—(C1-C4)Alk-phenyl, —SO2-phenyl group, or a —(C1-C4)Alk group; X completes a saturated or unsaturated cycle of 5 to 8 atoms, capable of bearing one or two —(C1-C4)Alk groups and/or two carbonyl groups; R3 and R′3 represent each independently a hydrogen or halogen atom, a —(C1-C6)Alk, hydroxy, —CN, —(C1-C6)alkoxy, —COR4 or Y—CR8R9—COR4 group; Y represents O or CH2; R4 represents a hydroxy, (C1-C6)alkoxy or —NR5R6 group; R5 and R6 independently represent a hydrogen atom, a —(C1-C4)Alk, group, aryl or heteroaryl optionally substituted by a R7 group, aralkyl or heteroaralkyl optionally substituted by a R7 group; or R5 and R6, with the nitrogen atom which bears them, form a saturated or unsaturated cycle of 5 to 7 atoms optionally substituted by a R7 group; and R7 represents a hydrogen or halogen atom, a hydroxy, —(C1-C4)Alk, —(C1-C6)alkoxy, —NH(C1-C4)Alk, —N(C1-C4)Alk2, —COO(C1-C4)Alk, aralkyl or heteroaryl group; R8 and R9 independently represent a hydrogen atom or a —(C1-C4)Alk group; their salts or solvates, the pharmaceutical compositions containing them, a method for preparing them and synthesis intermediates.

    摘要翻译： 本发明涉及式（1）的化合物，其中A是式（a）或（b）的基团，其中：R表示氢或卤素原子，-S（O）z（C1-C4） 是0,1或2，-NHSO 2（C 1 -C 4）Alk，-SO 2 NH（C 1 -C 4）Alk，-NHSO 2 - （C 1 -C 4）烷基 - 苯基或-NHSO 2 - 苯基， 卤素原子，（C1-C4）Alk基或（C1-C6）烷氧基; R1表示氢原子或 - （C1-C4）Alk，-CO（C1-C4）Alk， - （C1-C4）Alk-苯基或-CO-苯基，所述能够带有卤素原子或 - （C1-C4）Alk或（C1-C6）烷氧基; R2是氢原子，-SO2（C1-C4）Alk，-SO2-（C1-C4）烷基 - 苯基，-SO2-苯基或 - （C1-C4） X完成5至8个原子的饱和或不饱和的循环，能承载一个或两个 - （C 1 -C 4）Alk基团和/或两个羰基基团; R 3和R'3各自独立地表示氢或卤素原子，α-（C1-C6）Alk，羟基，-CN， - （C1-C6）烷氧基，-COR4或Y-CR8R9-COR4基团; Y表示O或CH 2; R4表示羟基，（C1-C6）烷氧基或-NR5R6基团; R 5和R 6独立地表示氢原子，任选被R 7取代的 - （C 1 -C 4）Alk，基团，芳基或杂芳基

    Propanolaminomethyltetralines, their preparation and pharmaceutical composition comprising same
    4.
    发明授权
    Propanolaminomethyltetralines, their preparation and pharmaceutical composition comprising same 失效

    公开(公告)号：US07115780B2

    公开(公告)日：2006-10-03

    申请号：US10497379

    申请日：2002-12-02

    申请人： Laura Barzaghi ,  Roberto Cecchi ,  Nunzia Viviani

    发明人： Laura Barzaghi ,  Roberto Cecchi ,  Nunzia Viviani

    IPC分类号： C07C211/19 ,  C07C213/02 ,  C07C307/02 ,  C07D263/52 ,  C07D265/36 ,  A61K31/18 ,  A61K31/42

    CPC分类号： C07C311/08 ,  C07C2602/10

    摘要： The invention concerns compounds of formula (I), wherein A is a group of formula (a) or (b), wherein: R represents a hydrogen or halogen atom, a —S(O)z(C1–C4)Alk wherein z is 0, 1 or 2, a —NHSO2(C1–C4)Alk, —SO2NH(C1–C4)Alk, —NHSO2—(C1–C4)Alk-phenyl or —NHSO2-phenyl group, said phenyl capable of bearing a halogen atom, a (C1–C4)Alk group or a (C1–C6)alkoxy group; R1 represents a hydrogen atom or a —(C1–C4)Alk, —CO(C1–C4)Alk, —(C1–C4)Alk-phenyl or —CO-phenyl group, said phenyl capable of bearing a halogen atom or a —(C1–C4)Alk or (C1–C6)alkoxy group; R2 is a hydrogen atom, a —SO2(C1–C4)Alk, —SO2—(C1–C4)Alk-phenyl, —SO2-phenyl group, or a —(C1–C4)Alk group; X completes a saturated or unsaturated cycle of 5 to 8 atoms, capable of bearing one or two —(C1–C4)Alk groups and/or two carbonyl groups; R3 and R′3 represent each independently a hydrogen or halogen atom, a —(C1–C6)Alk, hydroxy, —CN, —(C1–C6)alkoxy, —COR4 or Y—CR8R9—COR4 group; Y represents O or CH2; R4 represents a hydroxy, (C1–C6)alkoxy or —NR5R6 group; R5 and R6 independently represent a hydrogen atom, a —(C1–C4)Alk, group, aryl or heteroaryl optionally substituted by a R7 group, aralkyl or heteroaralkyl optionally substituted by a R7 group; or R5 and R6, with the nitrogen atom which bears them, form a saturated or unsaturated cycle of 5 to 7 atoms optionally substituted by a R7 group; and R7 represents a hydrogen or halogen atom, a hydroxy, —(C1–C4)Alk, —(C1–C6)alkoxy, —NH(C1–C4)Alk, —N(C1–C4)Alk2, —COO(C1–C4)Alk, aralkyl or heteroaryl group; R8 and R9 independently represent a hydrogen atom or a —(C1–C4)Alk group; their salts or solvates, the pharmaceutical compositions containing them, a method for preparing them and synthesis intermediates